ANGIOVIST 370 Drug Patent Profile
✉ Email this page to a colleague
When do Angiovist 370 patents expire, and when can generic versions of Angiovist 370 launch?
Angiovist 370 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in ANGIOVIST 370 is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Angiovist 370
A generic version of ANGIOVIST 370 was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
Summary for ANGIOVIST 370
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Patent Applications: | 190 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANGIOVIST 370 at DailyMed |
US Patents and Regulatory Information for ANGIOVIST 370
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ANGIOVIST 370 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 087723-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |